Nancy A. Grygiel, an insider at Amgen Inc (AMGN), recently sold 7,225 shares of the company at a price of $337.26 per share, resulting in a total transaction value of $2.44 million. Following this sale, Grygiel retains 7,225 shares of Amgen.
This transaction highlights the complex nature of insider selling, which can stem from various motivations such as diversification, tax planning, or personal financial needs. While significant selling activity may attract investor scrutiny, it does not inherently signal negative sentiment towards the company.
Amgen, a prominent player in the biotechnology sector, focuses on discovering, developing, manufacturing, and marketing human therapeutics. The company is headquartered in Thousand Oaks, California, and employs approximately 28,000 individuals. Its diverse portfolio includes treatments for serious conditions, with marketed products such as ENBREL, Otezla, and Repatha.
As of November 20, 2025, Amgen boasts a market capitalization of $184.4 billion, a trailing P/E ratio of 26.32, and an EPS of 12.94. The company also offers a notable dividend yield of 278.0%. Investors are anticipating upcoming earnings reports, with estimates of $5.80 EPS and $9.5 billion in revenue for the quarter ending August 3, 2026.
While insider transactions are required to be reported to the SEC, they should be viewed as part of a broader context. Investors are encouraged to consider patterns of activity across multiple insiders and timeframes rather than relying on isolated events.